Supporting Patients Through Treatment for Advanced NSCLC

EP: 1.Clinical Case: EGFR-Mutant (Exon 19 del) Advanced NSCLC

EP: 2.The Treatment Landscape For Advanced EGFR-Mutant NSCLC

EP: 3.Emerging Insights From MARIPOSA: OS Updates From Amivantamab/Lazertinib in Advanced NSCLC

EP: 4.Navigating CNS Disease in EGFR-Mutant NSCLC

EP: 5.From Trial to Practice: Integrating Amivantamab/Lazertinib in Advanced NSCLC

EP: 6.Patient Education and IRR Prophylaxis in Practice With Amivantamab/Lazertinib

EP: 7.Managing Dermatologic AEs With Amivantamab/Lazertinib: Updates From the COCOON Clinical Trial

EP: 8.The Multidisciplinary Approach to Care for Advanced NSCLC

EP: 9.Clinical Case: ALK-Positive Advanced NSCLC

EP: 10.Frontline Treatment Decisions in ALK+ NSCLC

EP: 11.Clinical Perspectives and Emerging Updates in Advanced NSCLC

EP: 12.Proactive Care in ALK-Positive NSCLC: Adverse Effect Counseling, Monitoring, and Management

Now Viewing

EP: 13.Supporting Patients Through Treatment for Advanced NSCLC

Video content above is prompted by the following:

Dose modification and treatment interruption strategies play crucial roles in maintaining patients on effective ALK inhibitor therapy while optimizing quality of life and treatment tolerability. Clinical guidelines provide clear frameworks for managing grade 2 or 3 toxicities through dose holds until resolution to baseline, followed by either rechallenge at the same dose or dose reduction depending on toxicity type and severity. For lorlatinib, dose reduction from 100 mg daily to 75 mg daily represents the standard approach for managing recurrent toxicities, with further reductions available if necessary.

Real-world management examples demonstrate the effectiveness of dose modification strategies in improving patient quality of life while maintaining treatment efficacy. Common scenarios requiring dose adjustment include elevated liver enzymes, increased creatinine kinase levels, symptomatic bradycardia with heart rates consistently below 60 beats per minute, and CNS toxicities including cognitive impairment or “brain fog” that interferes with daily functioning. Patient anxiety about dose reductions can be addressed through education about the potential for dose re-escalation once toxicities resolve and reassurance about maintained efficacy at reduced doses.

The multidisciplinary care team extends beyond the immediate oncology team to include clinical pharmacists for medication interaction monitoring, nurse navigators for appointment coordination and patient support, physical therapists for maintaining functional status, speech therapists for cognitive issues, psychology services for mood and anxiety management, registered dietitians for nutritional optimization, cardiology consultation for cardiovascular toxicity management, and palliative care teams for comprehensive symptom management and quality of life optimization. Early palliative care integration from diagnosis provides additional support layers for patients with stage IV lung cancer, addressing not only physical symptoms but also psychosocial needs and care coordination. This comprehensive approach ensures that patients receive holistic support throughout their treatment journey, optimizing both clinical outcomes and quality of life during advanced cancer treatment.